Insider Selling: Dev Ittycheria Unloads 2,000 Shares of athenahealth Stock (ATHN)
athenahealth (NASDAQ:ATHN) Director Dev Ittycheria unloaded 2,000 shares of the company’s stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $181.17, for a total value of $362,340.00. Following the completion of the transaction, the director now directly owns 8,574 shares in the company, valued at approximately $1,553,352. The transaction was disclosed in a filing with the SEC, which is available at this link.
athenahealth (NASDAQ:ATHN) traded up 3.04% during mid-day trading on Thursday, hitting $186.69. 626,338 shares of the company’s stock traded hands. athenahealth has a 1-year low of $82.01 and a 1-year high of $184.82. The stock’s 50-day moving average is $142.3 and its 200-day moving average is $125.9. The company has a market cap of $6.979 billion and a P/E ratio of 2588.29.
athenahealth (NASDAQ:ATHN) last announced its earnings results on Thursday, February 6th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.12. The company had revenue of $171.60 million for the quarter, compared to the consensus estimate of $168.39 million. During the same quarter in the previous year, the company posted $0.29 earnings per share. The company’s revenue for the quarter was up 47.5% on a year-over-year basis. On average, analysts predict that athenahealth will post $1.07 earnings per share for the current fiscal year.
A number of research firms have recently commented on ATHN. Analysts at RBC Capital initiated coverage on shares of athenahealth in a research note on Thursday. They set a “sector perform” rating on the stock. Separately, analysts at Cowen and Company upgraded shares of athenahealth from an “underperform” rating to a “market perform” rating in a research note on Thursday. They now have a $186.00 price target on the stock, up previously from $123.00. Finally, analysts at Goldman Sachs reiterated a “neutral” rating on shares of athenahealth in a research note on Monday. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $149.50.
athenahealth, Inc (NASDAQ:ATHN), is a business services company, which provides ongoing billing, clinical-related, and other related services to its customers.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.